Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia
| Autor: | C. Michel Zwaan, Gisela Barbany, Toby Trahair, Naomi Michels, Monique L. den Boer, Rosemary Sutton, Rob Pieters, Sabine Ebert, Marta Fiocco, Hester A. de Groot-Kruseman, Ajay Vora, Udo zur Stadt, Gabriele Escherich, Luciano Dalla-Pozza, Mats Heyman, Kjeld Schmiegelow, Amir Enshaei, Judith M. Boer, Anthony V. Moorman, Vincent H.J. van der Velden |
|---|---|
| Přispěvatelé: | Pediatrics, Immunology |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Down syndrome Neoplasm Residual Adolescent Disease-Free Survival Cohort Studies Ikaros Transcription Factor SDG 3 - Good Health and Well-being Internal medicine Humans Medicine Child Proportional hazards model business.industry Hazard ratio Articles Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Minimal residual disease Pediatric cancer Regimen Child Preschool Cohort Female Down Syndrome business Gene Deletion Cohort study |
| Zdroj: | The Lancet Haematology, 8(10), E700-E710. Lancet Publishing Group The Lancet Haematology, 8(10), E700-E710. ELSEVIER SCI LTD Michels, N, Boer, J M, Enshaei, A, Sutton, R, Heyman, M, Ebert, S, Fiocco, M, de Groot-Kruseman, H A, van der Velden, V H J, Barbany, G, Escherich, G, Vora, A, Trahair, T, Dalla-Pozza, L, Pieters, R, zur Stadt, U, Schmiegelow, K, Moorman, A V, Zwaan, C M & den Boer, M L 2021, ' Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia : a matched cohort study ', The Lancet Haematology, vol. 8, no. 10, pp. e700-e710 . https://doi.org/10.1016/S2352-3026(21)00272-6 The Lancet. Haematology |
| ISSN: | 2352-3026 |
| DOI: | 10.1016/S2352-3026(21)00272-6 |
| Popis: | Background: Patients with Down syndrome and acute lymphocytic leukaemia are at an increased risk of treatment-related mortality and relapse, which is influenced by unfavourable genetic aberrations (eg, IKZF1 deletion). We aimed to investigate the potential underlying effect of Down syndrome versus the effects of adverse cancer genetics on clinical outcome. Method: Patients (aged 1–23 years) with Down syndrome and acute lymphocytic leukaemia and matched non-Down syndrome patients with acute lymphocytic leukaemia (matched controls) from eight trials (DCOG ALL10 and ALL11, ANZCHOG ALL8, AIEOP-BFM ALL2009, UKALL2003, NOPHO ALL2008, CoALL 07-03, and CoALL 08-09) done between 2002 and 2018 across various countries (the Netherlands, the UK, Australia, Denmark, Finland, Iceland, Norway, Sweden, and Germany) were included. Participants were matched (1:3) for clinical risk factors and genetics, including IKZF1 deletion. The primary endpoint was the comparison of MRD levels (absolute MRD levels were categorised into two groups, low [cs] 4·3 [1·6–11·0]; p=0·0028), but not in the IKZF1 wild-type group (relapse at 5 years 5·8% [2·1–12·2] vs 8·1% [5·1–12·0]; HRcs 1·0 [0·5–2·1]; p=0·99). In addition to increased induction deaths (15 [6%] of 251 vs 69 [0·8%] of 8426), Down syndrome and acute lymphocytic leukaemia was associated with a higher risk of post-induction TRM compared with matched controls (TRM at 5 years 12·2% [7·0–18·9] vs 2·7% [1·3–4·9]; HRcs 5·0 [2·3–10·8]; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|